Publication | Closed Access

An Integrated Multiple-Analyte Pharmacokinetic Model to Characterize Trastuzumab Emtansine (T-DM1) Clearance Pathways and to Evaluate Reduced Pharmacokinetic Sampling in Patients with HER2-Positive Metastatic Breast Cancer

Breast OncologyMultiple-analyte Pharmacokinetic ModelPharmacokinetic ModelingMedicineClearance PathwaysPharmacologyImmune Checkpoint InhibitorBreast CancerPharmacotherapyCancer TreatmentOncologyRadiation OncologyTumor MicroenvironmentTrastuzumab Emtansine